John J V McMurray1, David L DeMets2, Silvio E Inzucchi3, Lars Køber4, Mikhail N Kosiborod5, Anna Maria Langkilde6, Felipe A Martinez7, Olof Bengtsson6, Piotr Ponikowski8, Marc S Sabatine9, Mikaela Sjöstrand6, Scott D Solomon10. 1. BHF Cardiovascular Research Centre, University of Glasgow, Glasgow, UK. 2. Department of Biostatistics and Medical Informatics, University of Wisconsin, Madison, WI, USA. 3. Section of Endocrinology, Yale University School of Medicine, New Haven, CT, USA. 4. Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark. 5. Saint Luke's Mid America Heart Institute and University of Missouri-Kansas City, Kansas City, MO, USA. 6. BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden. 7. National University of Cordoba, Cordoba, Argentina. 8. Wroclaw Medical University, Wroclaw, Poland. 9. TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA, USA. 10. Cardiovascular Division, Brigham and Women's Hospital, Boston, MA, USA.
Abstract
BACKGROUND: The aims of this study were to: (i) report the baseline characteristics of patients enrolled in the Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure (DAPA-HF) trial, (ii) compare DAPA-HF patients to participants in contemporary heart failure (HF) registries and in other recent HF trials, and (iii) compare individuals with diabetes, pre-diabetes and a normal glycated haemoglobin (HbA1c) in DAPA-HF. METHODS AND RESULTS:Adults with HF in New York Heart Association functional class ≥ II, a left ventricular ejection fraction ≤ 40%, an elevated N-terminal pro-B-type natriuretic peptide concentration and receiving standard treatment were eligible for DAPA-HF, which is comparing dapagliflozin 10 mg once daily to matching placebo. In patients without a history of diabetes, previously undiagnosed diabetes was defined as a confirmed HbA1c ≥ 6.5%. Among patients without known or undiagnosed diabetes, pre-diabetes was defined as a HbA1c ≥ 5.7% The remainder of patients, with a HbA1c < 5.7%, were defined as normoglycaemic. Of the 4744 patients (mean age 66 years; 23% women) randomized, 42% had known diabetes and 3% undiagnosed diabetes. Of the remainder, 67% had pre-diabetes and 33% normal HbA1c. Overall, DAPA-HF patients were generally similar to those in recent registries and in relevant trials and had high levels of background therapy: 94% angiotensin-converting enzyme inhibitor/angiotensin receptor blocker/angiotensin receptor-neprilysin inhibitor, 96% beta-blocker, and 71% mineralocorticoid receptor antagonist; 26% had a defibrillator. Patients with diabetes had worse HF status, more co-morbidity, and greater renal impairment but received similar HF therapy. Patients with diabetes received non-insulin hypoglycaemic therapy alone in 49%, insulin alone in 11%, both in 14%, and none in 26%. CONCLUSIONS: Patients randomized in DAPA-HF were similar to those in other contemporary HF with reduced ejection fraction (HFrEF) registries and trials. These patients were receiving recommended HFrEF therapy and those with diabetes were also treated with conventional glucose-lowering therapy. Consequently, DAPA-HF will test the incremental efficacy and safety of dapagliflozin in HFrEF patients with and without diabetes. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov Identifier NCT03036124.
RCT Entities:
BACKGROUND: The aims of this study were to: (i) report the baseline characteristics of patients enrolled in the Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure (DAPA-HF) trial, (ii) compare DAPA-HF patients to participants in contemporary heart failure (HF) registries and in other recent HF trials, and (iii) compare individuals with diabetes, pre-diabetes and a normal glycated haemoglobin (HbA1c) in DAPA-HF. METHODS AND RESULTS: Adults with HF in New York Heart Association functional class ≥ II, a left ventricular ejection fraction ≤ 40%, an elevated N-terminal pro-B-type natriuretic peptide concentration and receiving standard treatment were eligible for DAPA-HF, which is comparing dapagliflozin 10 mg once daily to matching placebo. In patients without a history of diabetes, previously undiagnosed diabetes was defined as a confirmed HbA1c ≥ 6.5%. Among patients without known or undiagnosed diabetes, pre-diabetes was defined as a HbA1c ≥ 5.7% The remainder of patients, with a HbA1c < 5.7%, were defined as normoglycaemic. Of the 4744 patients (mean age 66 years; 23% women) randomized, 42% had known diabetes and 3% undiagnosed diabetes. Of the remainder, 67% had pre-diabetes and 33% normal HbA1c. Overall, DAPA-HF patients were generally similar to those in recent registries and in relevant trials and had high levels of background therapy: 94% angiotensin-converting enzyme inhibitor/angiotensin receptor blocker/angiotensin receptor-neprilysin inhibitor, 96% beta-blocker, and 71% mineralocorticoid receptor antagonist; 26% had a defibrillator. Patients with diabetes had worse HF status, more co-morbidity, and greater renal impairment but received similar HF therapy. Patients with diabetes received non-insulin hypoglycaemic therapy alone in 49%, insulin alone in 11%, both in 14%, and none in 26%. CONCLUSIONS:Patients randomized in DAPA-HF were similar to those in other contemporary HF with reduced ejection fraction (HFrEF) registries and trials. These patients were receiving recommended HFrEF therapy and those with diabetes were also treated with conventional glucose-lowering therapy. Consequently, DAPA-HF will test the incremental efficacy and safety of dapagliflozin in HFrEF patients with and without diabetes. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov Identifier NCT03036124.
Authors: Su E Yeoh; Pooja Dewan; Pardeep S Jhund; Silvio E Inzucchi; Lars Køber; Mikhail N Kosiborod; Felipe A Martinez; Piotr Ponikowski; Marc S Sabatine; Scott D Solomon; Olof Bengtsson; Mikaela Sjöstrand; Anna Maria Langkilde; John J V McMurray Journal: Circ Heart Fail Date: 2020-11-09 Impact factor: 8.790
Authors: Mariam Elmegaard Malik; Charlotte Andersson; Paul Blanche; Maria D'Souza; Christian Madelaire; Bochra Zareini; Morten Lamberts; Søren Lund Kristensen; Naveed Sattar; John McMurray; Lars Køber; Christian Torp-Pedersen; Gunnar Gislason; Morten Schou Journal: Clin Res Cardiol Date: 2022-04-08 Impact factor: 5.460
Authors: Pardeep S Jhund; Piotr Ponikowski; Kieran F Docherty; Samvel B Gasparyan; Michael Böhm; Chern-En Chiang; Akshay S Desai; Jonathon Howlett; Masafumi Kitakaze; Mark C Petrie; Subodh Verma; Olof Bengtsson; Anna-Maria Langkilde; Mikaela Sjöstrand; Silvio E Inzucchi; Lars Køber; Mikhail N Kosiborod; Felipe A Martinez; Marc S Sabatine; Scott D Solomon; John J V McMurray Journal: Circulation Date: 2021-04-09 Impact factor: 29.690
Authors: Justin T Parizo; Jeremy D Goldhaber-Fiebert; Joshua A Salomon; Kiran K Khush; John A Spertus; Paul A Heidenreich; Alexander T Sandhu Journal: JAMA Cardiol Date: 2021-08-01 Impact factor: 30.154
Authors: Kieran F Docherty; Pardeep S Jhund; Brian Claggett; João Pedro Ferreira; Olof Bengtsson; Silvio E Inzucchi; Lars Køber; Mikhail N Kosiborod; Anna Maria Langkilde; Felipe A Martinez; Piotr Ponikowski; Marc S Sabatine; Mikaela Sjöstrand; Scott D Solomon; John J V McMurray Journal: JAMA Cardiol Date: 2021-11-01 Impact factor: 30.154